Product
Telotristat
Aliases
Xermelo
Name
Xermelo
INN Name
telotristat ethyl
FDA Approved
Yes
3 clinical trials
2 organizations
5 indications
1 document
Indication
Locally Advanced Neuroendocrine NeoplasmIndication
Metastatic Neuroendocrine NeoplasmIndication
Neuroendocrine TumorsIndication
Carcinoid SyndromeIndication
DiarrheaClinical trial
TELEHEART: Telotristat Ethyl in a Heart Biomarker StudyStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine TumorsStatus: Terminated, Estimated PCD: 2022-06-03
Clinical trial
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400Status: Withdrawn, Estimated PCD: 2023-02-01
Document
DailyMed Label: XermeloOrganization
Lexicon Pharmaceuticals, Inc.Organization
TerSera Therapeutics LLC